Age between 4–65 at enrollment |
Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator |
Clinically affected (defined as weakness on bedside evaluation in either a limb-girdle pattern or in a distal extremity) |
Genetically or functionally confirmed mutation in ANO5, CAPN3, DYSF, SGCA-G, or DNAJB6 |
History of
|
Willing and able to give informed consent and follow all study procedures and requirements |
Positive pregnancy test at any time point during the trial |